Ownership history in Prospect Financial Services LLC Β· 9 quarters on record
This page tracks every 13F SEC filing in which Prospect Financial Services LLC reported a position in ACURX PHARMACEUTICALS INC (ACXP). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β sourced directly from SEC EDGAR 13F filings.
π Prospect Financial Services LLC underperformed the S&P 500 by β132.5% annually on this ACXP position. Timing score: 33% (2/6 decisions correct). Average cost basis: $23.29. Maximum drawdown during holding period: β94.9%.
β Significantly underperformed the S&P 500 by 132.5% ann.
7 quarters analyzed
β οΈ Poor timing β buys often preceded drops, trims preceded rallies.
2 of 6 add/trim decisions correct
Best entry: $7.80 (2025 Q1) Β· Worst: $49.00 (2024 Q1)
πͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.
6 adds Β· 2 trims. Bought during 4 of 6 down-price quarters. π Consistently bullish β fund kept accumulating this position.
βοΈ Portfolio weight has remained relatively stable β conviction maintained.
Currently 0.03% of portfolio
β Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ 4 (annualised). Not investment advice.
As of 2025 Q4 β sorted by position size